Vidaza

Syros Pharmaceuticals leadership team
Biotech

Syros links SY-1425 combo to 50%-plus AML complete response rate

Seven of the 13 newly diagnosed AML patients with a certain biomarker had full complete responses after receiving the RARĪ± agonist and Vidaza.
Nick Paul Taylor Oct 25, 2019 10:15am
Screen of Nasdaq stock tickers

Karyopharm AML drug fails phase 2, giving stock whiplash

Mar 3, 2017 4:27am